Precision medicine in asthma: linking phenotypes to targeted treatments

被引:57
作者
Chung, Kian Fan [1 ,2 ]
机构
[1] Imperial Coll London, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England
[2] Imperial Coll London, Royal Brompton & Harefield NHS Trust, Res Resp Biomed Res Unit, London, England
关键词
asthma; biomarkers; phenotyping; precision medicine; UNCONTROLLED PERSISTENT ASTHMA; ADD-ON THERAPY; DOUBLE-BLIND; INHALED CORTICOSTEROIDS; MONOCLONAL-ANTIBODY; CLUSTER-ANALYSIS; MEPOLIZUMAB; EFFICACY; MULTICENTER; SAFETY;
D O I
10.1097/MCP.0000000000000434
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose of review Asthma is a heterogeneous disease consisting of different phenotypes that are driven by different mechanistic pathways. The purpose of this review is to emphasize the important role of precision medicine in asthma management. Recent findings Despite asthma heterogeneity, the approach to management has been on the basis of disease severity, with the most severe patients reserved for the maximum treatments with corticosteroids and bronchodilators. At the severe end, the recent availability of biologic therapies in the form of anti-IgE (omalizumab) and anti-IL5 therapies (mepolizumab and reslizumab) has driven the adaptation of precision medicine. These therapies are reserved for severe asthma with defined either allergic or eosinophilic background, respectively. Summary Unbiased definition of phenotypes or endotypes (which are phenotypes defined by mechanisms) is an important step towards the use of precision medicine in asthma. Although T2-high asthma has been defined with targets becoming available for treating allergic or eosinophilic asthma, the definition of non-T2 phenotypes remains a priority. Precision medicine is also dependent on the definition of biomarkers that can help differentiate between these phenotypes and pinpoint patients suitable for specific-targeted therapies. Thus, precision medicine links phenotypes (endotypes) to targeted treatments for better outcomes.
引用
收藏
页码:4 / 10
页数:7
相关论文
共 44 条
[1]   Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization [J].
Amur, S. ;
LaVange, L. ;
Zineh, I. ;
Buckman-Garner, S. ;
Woodcock, J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) :34-46
[2]   Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease [J].
Anderson, Gary P. .
LANCET, 2008, 372 (9643) :1107-1119
[3]   Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial [J].
Bleecker, Eugene R. ;
FitzGerald, J. Mark ;
Chanez, Pascal ;
Papi, Alberto ;
Weinstein, Steven F. ;
Barker, Peter ;
Sproule, Stephanie ;
Gilmartin, Geoffrey ;
Aurivillius, Magnus ;
Werkstrom, Viktoria ;
Goldman, Mitchell .
LANCET, 2016, 388 (10056) :2115-2127
[4]   Severe eosinophilic asthma: a roadmap to consensus [J].
Buhl, Roland ;
Humbert, Marc ;
Bjermer, Leif ;
Chanez, Pascal ;
Heaney, Liam G. ;
Pavord, Ian ;
Quirce, Santiago ;
Virchow, Johann C. ;
Holgate, Stephen .
EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (05)
[5]   Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma [J].
Busse, William W. ;
Holgate, Stephen ;
Kerwin, Edward ;
Chon, Yun ;
Feng, JingYuan ;
Lin, Joseph ;
Lin, Shao-Lee .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 188 (11) :1294-1302
[6]  
Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]
[7]   TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma [J].
Choy, David F. ;
Hart, Kevin M. ;
Borthwick, Lee A. ;
Shikotra, Aarti ;
Nagarkar, Deepti R. ;
Siddiqui, Salman ;
Jia, Guiquan ;
Ohri, Chandra M. ;
Doran, Emma ;
Vannella, Kevin M. ;
Butler, Claire A. ;
Hargadon, Beverley ;
Sciurba, Joshua C. ;
Gieseck, Richard L. ;
Thompson, Robert W. ;
White, Sandra ;
Abbas, Alexander R. ;
Jackman, Janet ;
Wu, Lawren C. ;
Egen, Jackson G. ;
Heaney, Liam G. ;
Ramalingam, Thirumalai R. ;
Arron, Joseph R. ;
Wynn, Thomas A. ;
Bradding, Peter .
SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (301)
[8]   Airway microbial dysbiosis in asthmatic patients: A target for prevention and treatment? [J].
Chung, Kian Fan .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (04) :1071-1083
[9]   Neutrophilic asthma: a distinct target for treatment? [J].
Chung, Kian Fan .
LANCET RESPIRATORY MEDICINE, 2016, 4 (10) :765-767
[10]   Targeting the interleukin pathway in the treatment of asthma [J].
Chung, Kian Fan .
LANCET, 2015, 386 (9998) :1086-1096